Taliaz Announces Successful End of Enrollment to its PREDICTIX Mental Health Study with Leading French Hospital, APHP Share Article New study provides psychiatrists with pioneering clinical support tool to inform antidepressant prescribing enabling improved quality of care, while saving time and lowering costs Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX “We are excited by the very encouraging early positive results we are seeing from the APHP study. As demand for our solution accelerates driven by the COVID-19 pandemic, we look forward to expanding our commercial pilots across Europe," said Dekel Taliaz, CEO of Taliaz